Curbing Resistance Development:Maximizing the Utility of Available Agents

BACKGROUND: Ventilator-associated pneumonia (VAP) in hospital intensive care units (ICUs) is associated with high morbidity and mortality.Effective treatment of VAP can be challenging due to a high prevalence of Pseudomonas aeruginosa and multidrug-resistant (MDR) pathogens as causative organisms. O...

Descripción completa

Detalles Bibliográficos
Autor principal: Burgess, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2009
Materias:
Cea
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437894/
https://www.ncbi.nlm.nih.gov/pubmed/19505173
http://dx.doi.org/10.18553/jmcp.2009.15.s5.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437894/
https://www.ncbi.nlm.nih.gov/pubmed/19505173
http://dx.doi.org/10.18553/jmcp.2009.15.s5.5

Ejemplares similares